Eilaf Distributing Saladax's My5-FU Test in Egypt, Other Parts of Middle East | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax Biomedical said today that Eilaf Pharma will exclusively distribute the My5-FU diagnostic test in Egypt and the Middle East North African region.

Saladax's test allows physicians to determine optimal dosing of the 5-fluorouracil (5-FU) anti-cancer drug for patients, and is the first of the Bethlehem, Penn.-based firm's dose management tests to be commercially available.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.